Results 161 to 170 of about 25,109 (253)
HERTHENA-PanTumor01: a phase II study of patritumab deruxtecan (HER3-DXd) in previously treated advanced solid tumors. [PDF]
Future OncolPowles T, Bhatia A, Burtness B, Kogawa T, Nishina T, Nakayama I, Fountzilas C, Castillo DR, McKean M, Meric-Bernstam F, Colombo N, Smithy JW, Fayette J, Chandra S, Sternberg DW, Jin F, Sullivan K, Yueh S, Clinthorne G, Aguilo AE, Kudchadkar R, Hayashi H. +21 moreeuropepmc +1 more sourceNovel Humanized Anti-HER3 Antibodies: Structural Characterization and Therapeutic Activity. [PDF]
Antibodies (Basel)Muzi A, Arriga R, Bulfaro G, Fata F, Costanzo A, Chiarini V, Cappelletti M, Ferrara FF, Bucci F, Montemiglio LC, Savino C, Marra E, Ciliberto G, Aurisicchio L, Vallone B, Roscilli G. +15 moreeuropepmc +1 more sourcePI3Kα Inhibitor and Degrader Inavolisib Can Co-opt FGFR2 to Enhance Responses in Patients with PIK3CA-Mutated Solid Tumors and in Preclinical Models. [PDF]
Clin Cancer ResJuric D, Song K, Johnson RM, Accordino MK, Bedard PL, Cervantes A, Gambardella V, Hamilton E, Italiano A, Kalinsky K, Krop IE, Oliveira M, Saura C, Schmid P, Turner NC, Varga A, Gendreau S, Hwang MS, Kuang Z, Lau JT, Lin E, Pham T, Maddalo D, Rees MG, Ronan MM, Roth JA, Martin S, Sodir NM, Sokol ES, Whitfield ZJ, Wong A, Yauch RL, Aimi J, Cheeti S, Fredrickson J, Hilz S, Hafner M, Hutchinson KE, Jin Y, Peters U, Zingg D, Royer-Joo S, Shankar N, Schutzman JL, Jhaveri KL, Dey A. +45 moreeuropepmc +1 more sourceIzalontamab (SI-B001), a Novel EGFRxHER3 Bispecific Antibody in Patients with Locally Advanced or Metastatic Epithelial Tumor: Results from First-in-Human Phase I/Ib Study. [PDF]
Clin Cancer ResXue J, Ma Y, Zhao Y, Wang Y, Hong W, Huang Y, Yang Y, Fang W, Hong S, Zhang Y, Liu Q, Zhu Y, Zhu H, Xiao S, Zhang L, Zhao H. +15 moreeuropepmc +1 more sourceNRG1 Fusions in NSCLC: Being eNRGy Conscious
Lung Cancer: Targets and TherapyBrinda Gupta, Laura Gosa Barrett, Stephen V Liu Lombardi Comprehensive Cancer Center, Georgetown University, Washington, DC, USACorrespondence: Stephen V Liu, Georgetown University, Lombardi Comprehensive Cancer Center, 3800 Reservoir Road NW, Washington,Gupta B, Gosa Barrett L, Liu SVdoaj A Two-in-One Antibody against HER3 and EGFR Has Superior Inhibitory Activity Compared with Monospecific Antibodies [PDF]
, 2011 Gabriele Schaefer, Lauric Haber, Lisa Crocker, Steven Shia, Lily Shao, Donald Dowbenko, Klára Tótpál, Anne Wong, Chingwei V. Lee, Scott Stawicki, Robyn Clark, Carter T. Fields, Gail D. Lewis Phillips, Rodney A. Prell, Dimitry M. Danilenko, Yvonne Franke, Jean-Philippe Stéphan, Ji‐Young Hwang, Yan Wu, Jenny Boström, Mark X. Sliwkowski, Germaine Fuh, Charles Eigenbrot +22 moreopenalex +1 more sourceSupplementary Tables and Figures from Efficacy and Safety of Patritumab Deruxtecan (HER3-DXd) in EGFR Inhibitor–Resistant, <i>EGFR</i>-Mutated Non–Small Cell Lung Cancer
, 2023 Pasi A. Jänne, Christina S. Baik, Wu‐Chou Su, Melissa L. Johnson, Hidetoshi Hayashi, Makoto Nishio, Dong‐Wan Kim, Marianna Koczywas, Kathryn A. Gold, Conor E. Steuer, Haruyasu Murakami, James Chih‐Hsin Yang, Sang‐We Kim, Michele Vigliotti, Rong Shi, Zhenhao Qi, Yang Qiu, Lihui Zhao, David Sternberg, Channing Yu, Helena A. Yu +20 moreopenalex +2 more sourcesPatritumab deruxtecan in HR<sup>+</sup>HER2<sup>-</sup> advanced breast cancer: a phase 2 trial. [PDF]
Nat MedPistilli B, Mosele F, Corcos N, Pierotti L, Pradat Y, Le Bescond L, Lacroix-Triki M, Nachabeh G, Alfaro A, Catelain C, Job B, Mami-Chouaib F, Badel S, Farace F, Oulhen M, Kannouche P, Tran DTN, Droin N, Vicier C, Frenel JS, D'Hondt V, Dalenc F, Bachelot T, Ducoulombier A, Benderra MA, Loirat D, Mayeur D, Deluche E, Deneuve J, Cheikh-Hussin R, Guyader P, Signolle N, Godefroy K, Talbot H, Vakalopoulou M, Christodoulidis S, Bernard E, Koudou Y, Sporchia A, Suto F, Li L, Sternberg DW, Michiels S, André F, Sellami D, Montagnac G. +45 moreeuropepmc +1 more source
